Medical professionals
At Mirum, we’re committed to nurturing our relationship with the scientific and medical communities by supporting medical education and scientific exchange. We also invest in research dedicated to addressing unmet needs for people living with rare disease.
Novel treatments for rare diseases
Learn more about our FDA-approved medicines developed to help address rare and challenging conditions.
Discover our latest published research and scientific contributions
Explore a collection of our published studies and presentations, showcasing our commitment to advancing science and improving patient care.
Clinical trials
Mirum has active clinical trials in several areas of rare disease. For more information about our clinical trials, please visit our Pipeline page.
Expanded access and compassionate use programs
Mirum operates a limited early/expanded access program in some countries outside of the U.S., offering access to LIVMARLI® (maralixibat) for eligible patients with Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). Programs are conducted in compliance with applicable health authority guidance for the purpose of facilitating patient access for those with life-threatening diseases for which there are limited to no approved treatments or clinical trial options.
For more information, physicians outside of the U.S. can contact medicineaccess@clinigengroup.com.
Mirum’s Expanded Access Program (EAP) offers access to LIVMARLI for eligible patients with ALGS and progressive familial intrahepatic cholestasis (PFIC).
- Physicians in Canada and the U.S. who are interested in the ALGS EAP should contact mirumalgs@clinigengroup.com
- Physicians in Canada and the U.S. who are interested in the PFIC EAP should contact mirumPFIC@clinigengroup.com
- Physicians outside of Canada and the U.S. who are interested in the PFIC or ALGS EAP should contact medicineaccess@clinigengroup.com
- To learn more about Mirum’s open clinical trials, please visit www.clinicaltrials.gov
Compassionate Use
Mirum may consider providing an investigational therapy to an individual patient outside of a clinical trial when an appropriate program or regulatory pathway is available.
Zilurgisertib Compassionate Use Program for FOP
A compassionate use program for investigational zilurgisertib is currently available in the United States for eligible patients 12 years of age and older with fibrodysplasia ossificans progressiva (FOP).
Mirum continues to assess potential access pathways in additional countries, as appropriate.
For licensed physicians
For information about the zilurgisertib Compassionate Use program, contact compassionateuse@mirumpharma.com
Medical information
Mirum’s Medical Information team is dedicated to serving healthcare providers and patients by providing information to better inform the use of Mirum’s medicines. The Medical Information team also receives and processes safety information, including reports of unwanted side effects or other problems affecting patients.
Healthcare professionals who would like to speak with a medical expert or request medical information may complete the Medical Information Request Form (MIRF).
Alternatively, healthcare professionals may contact our Medical Information team directly by email or by calling the appropriate number listed in the section below:
• U.S. – medinfo@mirumpharma.com
• Canada – medinfoCANADA@mirumpharma.com
• Europe – medinfoEU@mirumpharma.com
Reporting adverse events
To report an adverse event or product complaint relating to LIVMARLI® (maralixibat), CHOLBAM® (cholic acid), or CTEXLI® (chenodiol), please contact 1-855-MRM4YOU (1-855-676-4968).
To report an adverse event or product complaint outside of the U.S., please contact us by dialing your country-specific phone number below:
Country
Phone number
Canada
Europe
Universal Toll-Free Phone Number: +800 4041 8081 (alternately: 00 800 4041 8081)
Switzerland
Belgium
Netherlands
Germany
France
United Kingdom
Italy
Portugal
Spain